ClinicalTrials.gg
RecruitingNCT05494034Updated Nov 9, 2023

Yield of Implantable Cardiac Monitoring Device in Patients With Acute Ischemic Stroke.

An interventional study of Reveal LINQTM in Stroke, Acute, Stroke and Stroke, Ischemic, sponsored by National and Kapodistrian University of Athens. Recruiting at 1 site in Greece. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-11-09.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National and Kapodistrian University of Athens · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
40 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Ischemic Stroke with a site in Greece — 8 open to participants now, 11 under way, 4 of them phase 3. Ischemic Stroke · Greece.

Planned enrollment
15th of 16
200 · median 866
Started
2023
with 3 others
No phase
2 of 25
1 open now
Primary completion
2027-01
later than 4 of 10 live
Registered
16th of 25
by date

Among the 25 studies in Ischemic Stroke with a site in Greece, this one is the 15th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2023, is one of 2 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 16th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

8 of the 25 studies in Ischemic Stroke with a site in Greece are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 40 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Ischemic Stroke with a site in Greece, or all of them as a file.
02

Study summary

In this prospective cohort study, the investigators aim to investigate the incidence of ICM-detected AF in unselected ischemic stroke patients and its association with anticoagulation initiation and stroke recurrence.

Read the detailed description

The study will be conducted among 4 tertiary centers of the cardioneurology network in the Athens Metropolitan area ("Attikon" University Hospital, Hippokrateion Hospital, "Georgios Gennimatas" General Hospital of Athens, NIMITS General Hospital of Athens). The Second Department of Neurology of the National and Kapodistrian University of Athens in "Attikon" University Hospital would also act as the coordinating center, comprising of a research group with significant clinical experience and numerous publications on PCM and stroke.

Consecutive acute ischemic stroke or TIA patients aged 40 years or older will be enrolled. Diagnosis of acute ischemic stroke will be based on clinical and neuroimaging evaluation [brain computed tomography (CT) scan or magnetic resonance imaging (MRI) scan]. Classification of stroke will be defined using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. Patients with incomplete evaluation will be excluded, as previously described. Patients with known or newly detected AF at hospitalization will also be excluded. Stroke patients of all other etiologies presenting a HAVOC score ≥4 will be included in the study. Informed consent for participation in the study will be obtained from the patients or guardians of patients.

Sample size

Similar to previous studies, approximately 200 eligible patients will be recruited during a 4-year period (50 patients/year). Based on a retrospective analysis of the local stroke registry and considering the eligibility criteria for this study, it is estimated that at least 1,000 stroke patients should be screened in order to enroll 200 participants.

Baseline Evaluation

All demographics and vascular risk factors will be prospectively recorded for all patients using standard definitions. Complete hematological and biochemical screening, as well as immunological and thrombophilia testing where indicated, will be performed. A comprehensive stroke etiopathogenic evaluation will be performed, including neuroimaging with brain computed tomography (CT) and / or magnetic resonance imaging (MRI), vascular imaging (cervical duplex ultrasound, transcranial Doppler, CT angiography and / or magnetic resonance [MR] angiography), ECG, transthoracic and/or transesophageal echocardiography and 24-to-48-hour Holter-ECG monitoring.

In particular, among the risk factors assessed, the age at inclusion, the number of atrial premature beats during the Holter-ECG monitoring, the location of index ischemic stroke (cortical versus deep), the brain natriuretic peptide (BNP) values, the presence of left atrial enlargement as diagnosed according to the guidelines of the American Society of Echocardiography, the HAVOC score (hypertension, age, valvular heart disease, peripheral vascular disease, obesity, congestive heart failure, coronary artery disease), the CHA₂DS₂-VASc score and the HAS-BLED score will be also recorded.

Stroke severity on admission will be assessed with the use of the National Institute of Health Stroke Scale (NIHSS) score by certified neurologists. Stroke classification according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) will be performed by certified neurologists, comprising of five stroke subtypes: (a) large-artery atherosclerosis; (b) cardioembolism; (c) small-vessel occlusion; (d) stroke of other determined etiology; and (e) stroke of undetermined etiology.[23] Interventions All included patients will receive secondary stroke prevention treatment and long-term management depending on the stroke subtype and according to current guidelines.

All included patients will have long-term heart rate monitors (Reveal LINQ; Medtronic) implanted subcutaneously under local anesthesia in the left chest region. During monitoring time, all patients with ICM will be evaluated clinically and electrocardiographically for up to 3 years following hospital discharge. Follow-up visits will be performed at the stroke outpatient clinic of our institution by outpatient visits and / or telephone, as dictated by their clinical status and at the discretion of the treating vascular neurologist, as previously described. All ICM recordings will be reviewed by a specialized cardiologist. All included patients will also be monitored with annual MRI scans for up to 3 years.

In the cases of AF detection, anticoagulant treatment may be initiated at the discretion of the treating physician, considering that the CHA₂DS₂-VASc score of the included patients will be at least 2 points, due to the history of stroke.

Statistical Analysis

Continuous variables will be presented as mean ± SD (normal distribution) and as median with interquartile range (IQR, skewed distribution). Categorical variables will be presented as number of patients and the corresponding percentages. Statistical comparisons between two groups (AF detected and no-AF detected) will be performed using χ2 test, or in case of small expected frequencies, Fisher's exact test. Continuous variables will be compared by the use of the unpaired t test or Mann-Whitney U test, as indicated. Cumulative probabilities of AF by risk factors will be displayed according to the Kaplan-Meier method. Event rates will be compared using the log-rank statistic. Univariable and multivariable Cox proportional hazards regression models will be used to determine predictors of AF. Baseline variables having differences with a significance level \<0.10 will be considered as candidates for multivariable time-to-event AF models. Statistical significance will be achieved if the p value is ⩽0.05 in multivariable logistic regression analyses. The Statistical Package for Social Science (SPSS Inc, Armonk, NY, USA; version 23.0 for Windows) will be used for statistical analyses.

03

Conditions studied

  • Stroke, Acute
  • Stroke
  • Stroke, Ischemic
  • Atrial Fibrillation

Browse trials for

04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 200 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

National and Kapodistrian University of Athens is the lead sponsor of 178 studies on the registry; 56 are open to participants now.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consecutive acute ischemic stroke or patients aged 40 years or older will be enrolled.
  • Diagnosis of acute ischemic stroke will be based on clinical and neuroimaging evaluation [brain computed tomography (CT) scan or magnetic resonance imaging (MRI) scan].
  • Stroke patients of all other etiologies (apart AF) presenting a HAVOC score ≥4 will be included in the study.
  • for participation in the study will be obtained from the patients or guardians of patients.

Exclusion criteria

Exclusion Criteria:

  • Patients with incomplete evaluation will be excluded, as previously described. [22] -Patients with known or newly detected AF at hospitalization will also be excluded.
  • Not providing .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    implantable cardiac monitoring device ("Reveal LINQTM")

    All included patients will have long-term heart rate monitors (Reveal LINQ; Medtronic)

    Device: Reveal LINQTM

Interventions

  • DeviceReveal LINQTM

    implantable cardiac monitoring device ("Reveal LINQTM")

07

What researchers measure

Primary outcomes

  1. Paroxysmal Atrial Fibrillation > 120 seconds

    the incidence of paroxysmal AF lasting 120 seconds or more in included patients evaluated with ICM.

    Time frame: 3 years

Secondary outcomes

  1. Paroxysmal Atrial Fibrillation > 6 minutes

    B) the incidence of paroxysmal AF lasting 6 minutes or more in included patients evaluated with ICM.

    Time frame: 3 years

  2. anticoagulant initiation

    C) the incidence of anticoagulant initiation among included patients.

    Time frame: 3 years

  3. recurrent ischemic strokes

    D) the incidence of recurrent ischemic strokes in included patients evaluated with ICM at follow-up according to paroxysmal AF duration.

    Time frame: 3 years

  4. subclinical infracts on follow-up MRI

    E) the incidence of subclinical infracts on follow-up MRI scans according to paroxysmal AF duration.

    Time frame: 3 years

  5. major hemorrhagic events

    F) the incidence of major hemorrhagic events in included patients evaluated with ICM at follow-up according to paroxysmal AF duration.

    Time frame: 3 years

  6. stroke subtypes

    G) the possible correlation between stroke subtypes and AF detection.

    Time frame: 3 years

  7. biomarkers

    H) the possible correlation of several baseline risk factors (including age, stroke location, BNP values, number of atrial premature beats, left atrial enlargement, HAVOC, CHA₂DS₂-VASc and HAS-BLED scores) with AF detection.

    Time frame: 3 years

  8. comparison versus historical cohort

    I) the comparison of the rates of recurrent stroke among the patients included in the present cohort and undergoing ICM versus historical controls that were evaluated by the standard 24-hour Holter-ECG monitoring.

    Time frame: 3 years

08

Study locations

1 of 1 sites recruiting
  • Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
    Athens, 12462, Greece
    Recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jan 2027, 43 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 43 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2022
First posted
Aug 9, 2022
StartActual
May 5, 2023
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2030
Last update
Nov 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05494034
Responsible party
Georgios Tsivgoulis (Professor & Chairman of Second Department of Neurology, School of Medicine, National & Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece, National and Kapodistrian University of Athens) — Principal investigator
First posted
Aug 9, 2022
Start date
May 5, 2023
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Nov 9, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion